account adjust acquisition-rel cost certain
signific item
conjunct model note issu today issu new
model sale estim intact although ep forecast rais higher margin
assumpt rate market perform keytruda success partial off-set
eros product pipelin visibl limit june analyst meet could
bring news chang outlook
ep estim rais vs consensu
vs consensu
ep compound-annual-growth-rate remain mrk estim ep growth remain bit
sale estim rais vs consensu
vs consensu lower
sale compound-annual-growth-rate unchang merck
estim sale growth remain bit industri averag
keytruda pembrolizumab sale estim lower
reduct
project revenu melanoma larg off-set increas rcc sale
forecast hand chang tumor led modest reduct
total keytruda sale ww share estim
oper margin estim rais
project gpm expand
 grow sg compound forecast
oper margin expans
two goal june analyst meet nyc highlight pipelin
growth opportun beyond keytruda facilit interact broader line-up
manag rel product beyond keytruda lynparza parp lenvima vegf
inhibitor gardasil hpv vaccin certainli subject much discuss
latter particularli relat opportun china anti-infect vaccin
portfolio competit advantag provid much visibl
past remain skeptic pneumococc valent vaccin program given
nnrti hiv product like receiv focu includ vericiguat ref heart
failur data gefapix cough endometriosi pain also explor
ipf migraine/oth pain state long sought januvia follow-on would
surpris hear news regard news could game-chang
pleas see page report import disclosur
merck competit posit line lung cancer clear posit merck face
uncertainti includ januvia outlook competit market competit pressur
isentress zostavax thin pipelin believ risk balanc opportun
therefor remain market perform stock
uptak keytruda nsclc
keytruda data readout variou tumor
keytruda approv
lynparza eu approv ovarian
oper margin improv
expect
new product unabl off-set declin
januvia zostavax isentress
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
cowen compani
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
cowen compani
 patent expir glenmark enter month exclusivityzetia patent expir gener launch ezetimibecozaar/hyzaar arb hypertens gener competitionvytorin exclus laps patent expir lost patent case euvytorin ezetimibe/simvastatin improve-it achiev endpoint garner fda labelintegrilin revenu repurchas milleniumzocor cholesterol reduct patent expir develop zetia lipitor market eu market riociguat solubl guanyl cyclas sgc modul approv eu pah cteph japan phase heart failur victoria ref-hf primari complet januari part bayer patent expir littl eros japan despit patent market bridion market eu japan eu patent exp sugammadex anesthesia revers suvorex insomnia orexin neuropeptid approv us japan yet file eu schizophrenia phase iiremeron antidepress patent expir januari major sale ex-u maxalt/maxalt mlt patent expir maxalt/maxalt mlt patent expir eumaxalt/maxalt mlt agonist anesthesia patent expir cowen
cowen compani
 qd market blunt erosionisentress qd approv eu hiv integras inhibitor treatment resist nave approv gilead gsk tivicay pose competitionnoxafil patent expir eu patent expir posaconazol oral antifung approv prophylaxi oral candidiasi cubicin advers court decis allow gener first gener teva launch sale nv modest royaltiescubicin cubist acquir launch competit landscap pressureszepati launch eu japan competit landscap pressureszepati hepat grazoprevir proteas inhibitor elbasvir competit landscap ceftolozane/tazobactam ww right ex asia-pacif gram neg infect habp/vabp pdufa difficil bezlotoxumab tx difficil associ diarrhea cdad approv medarex/ma biolog labspifeltro mono /delstrigo doravirin nnrti hiv qd dose approv letermovir cmv prophylaxi transplant patient roll-out tedizolid gram po infect launch phase habp/vabp hiv infect phase relebactam imipenem/cilastatin cuti/ciai pdufa roch pegasys/copegu pressur new drug clip durat therapyintron support use oncolog applicationsribavirin/rebetol older modalityintron substanc patent exp formul patent exp settlement allow gener launch aug ou patent expiredcancida antifung qd iv new indic price share eros due competitioninvanz patent expir compound composit gener launch broad spectrum carbapenem oral im iv qdprimaxin emerg market-drivenprimaxin bolster sale effort blunt eros patent expir proteas inhibitor aid stocrin certain fgn mkt patent exp older antibioticstot cowen
cowen compani
 golimumab ra pa uc approv eu canada competit clip growtharcoxia approv market countriesremicad crohn uc ra pa earli ra psoriasi patent expir biosimilar exposur marketstot approv tumor type includ melanoma lung chl bladder msi-hkeytruda eu approv melanoma lung chl bladder gastric mh-cr cervicalkeytruda antibodi mani tumor type melanoma phase saha cutan t-cell lymphoma roll-out underway clinic trial underwayemend aprepit substanc antagonist emesi patent exp oral iv franchis oral/ivtemodar teva launch gener gener japan pat exp eu temodar chemotherapeut aa gbmazn lynparza/selumetinib record sale net cog sg record lineeisai lenvima record sale net cog sg record linetot gener launch over-the-counter product also pressurenasonex gener eu allerg rhinitisdulera asthma market copd longer pursu dulera launch copd four market asthma market dulera mometasone/formoterol ics/laba twice daili competit pressuressingulair patent expir patent expir eu includ month pedi exclus japansingulair ph chronic acut cough includ idiopath pulmonari fibrosi pain migrain endometriosi ph iiasmanex market asmanex market countriesasmanex asthma dri powder qd inhal corticosteroid patent devic formul expir beta agonist asthma cfc hfa complet cowen
cowen compani
 continuedclarinex small market retainedclarinex claritin rx/otc sold bayer ag tax part consum transact close claritin/clarinex asthma older product europetot nrx share patent expir pedi exclus could add monthsjanuvia patient expir exclus could add month januvia qd antidiabet competit threat given proven cv ertugliflozin diabet inhib w/ app mono combo w/sitagliptin metformin omarigliptin diabet qweek inhibitor market japan file plan diabet phase ii clinic holdtot competit gsk shingrix prompt zostavax declin sale reflect dissolut spmsd jv ad herp zoster vaccin adult year singl sq dose plu booster investigatedproquad mmr ii varivax mmr ii varivax sale reflect dissolut spmsd jv ad mmr ii varivax could support health initiativesrotateq sale reflect dissolut spmsd jv ad rotaviru vaccin oral liquid good safeti profil market ww competit gskgardasil/gardasil approv year old femal male sale gardasil two dose approv fda/cdcgardasil/gardasil sale reflect dissolut spmsd jv ad approv two dose regimen china launch boostsgardasil/gardasil hpv vaccin borrow cdc stockpil refil hexaval combin pediatr vaccin approv eu issu refil pneumoconjug vaccin phase valent tough competit cytomegaloviru vaccin phase respiratori syncyti viru rsv phase ebola vaccin phase pneumovax use dose post prevnar boost tie birth cohortpneumovax support integr spmsd jv marketspneumovax pneumococc vaccin adultstot cowen
cowen compani
 psoriasi moder potenc steroid patent exp compound cream lotion implanon/nexplanon patent expir patent expir implant contracept patent expir juli progesteron/estrogen market eu exclus pursu corifollitropin alpha infertil market eu exclus pursu nuvar patent expir april gener yet launchednuvar contracept vagin contracept patent expir septemb aq aq aq follitropin beta inject patent expir june oral contracept patent expir decemb contracept patent expir septemb oral contracept patent expir march contraception/women cowen
cowen compani
 bph gener competit fosamax osteoporosi gener launch patent expir bald domin small acceler time upper lower gi recoveri post surgeri cubistoth ivomec merial othertot healthlivestock leader vaccinescompanion anim bravecto oral approv may key driver line extens launchinganim boost smaller acquisit antelliq cattl monitor close anim bravecto numer therapeut productsanim line estim anim market growth guidanc includ fx impact cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
